Trial Profile

A Phase I, Open Label, Single Dose Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Napabucasin (Primary)
Indications Colorectal cancer; Gastrointestinal cancer; Glioblastoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology

Most Recent Events

30 Oct 2019 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
17 Sep 2018 Status changed from recruiting to completed.
18 May 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com